Navigation Links
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
Date:6/2/2009

. This study was conducted in more than 100 clinical sites throughout North America. The objective of the study was to show that a 10-day course of fidaxomicin was at least as efficacious (non-inferior) and safe as a 10-day course of Vancocin (vancomycin hydrochloride capsules, USP) for the treatment of CDI.

The primary endpoint of the study was clinical cure defined as patients requiring no further CDI therapy two days after completion of study medication, as determined by the investigator. The secondary endpoint evaluated CDI recurrence up to four weeks post therapy with recurrence defined as the return of diarrhea associated with CDI confirmed by a positive toxin test. Global cure was defined as patients who were cured and did not have a recurrence.

About Clostridium Difficile Infection

CDI has become a growing problem in hospitals, long-term care facilities and in the community. It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death. CDI typically develops from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, allowing C. difficile bacteria to flourish.

Current therapeutic options for CDI include metronidazole and oral vancomycin. However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of antibiotic administration.

Primary risk factors for CDI include broad-spectrum antibiotic use, advanced age (over 65), emerging hyper-virulent strains (BI /NAP1/027, 078, 001) of C. difficile, and previous exposure to CDI that lead to recurrence. Higher incidence, increased treatment failures, and recurrence with standard therapies have resulted in greater awarene
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... PALO ALTO, Calif. , May 17, 2013 ... that it has achieved 50% enrollment of the ... trial to evaluate the safety and preliminary efficacy ... Progenitor Cells) therapy for Knee Osteoarthritis (KOA). To ... Effect (SAE) reported. The Phase I ...
(Date:5/17/2013)... Calif. , May 17, 2013 /PRNewswire-iReach/ -- ... has been reached with Switzerland ... of anti-infective human monoclonal antibody (mAb) products, and ... human mAb products for treatment of infections by ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s skin,( says skin ... known to react more aggressively when hormones change, and acne ... other acne causing factors like P.acnes bacteria and excess dirt ... unsightly acne scars. Adult acne treatment, Probiotic Action shares new ... to reduce and prevent acne scarring. , In order to ...
(Date:5/17/2013)... 17, 2013 RURO Inc. is ... 4.1, a versatile refinement to the smart management ... improves its advanced methodical management for transgenic animal ... 4.1. The network-based platform provides user access with ... While continuing to emphasize streamlined tasks, such as ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... Inhibitor (human)] Commercial Launch --EXTON, Pa., Feb. 24 ViroPharma ... results for the fourth quarter and year ended December 31, ... , ... 2008; , Initiated commercial ...
... DiagnosticsSALT LAKE CITY, Feb. 24 Axial Biotech, ... development of molecular diagnostic technologies, announced today that ... management team as the company,s new Vice President ... directly to Kenneth Ward, M.D., Chairman and Chief ...
... 23 Smith & Nephew, Inc.,(NYSE: SNN ... the,introduction of VISIONAIRE Patient Matched instrumentation for use in ... that,uses a patient,s MRI and x-rays to create custom ... of high performance knee implants. , ...
Cached Biology Technology:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 12Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development 2Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 2Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 3
(Date:5/16/2013)... developed at MIT may someday eliminate the need ... monitor their blood-sugar levels and inject themselves with ... glucose levels in the body and respond by ... the function of pancreatic islet cells, which are ... this type of system could ensure that blood-sugar ...
(Date:5/16/2013)... Philadelphia, PA, May 16, 2013 The relationship ... intelligence (IQ) has not been clear. Schizophrenia is ... functional disability. There are clues that reduced IQ ... schizophrenia. For example, reduced cognitive ability may precede ... may be present in healthy relatives of people ...
(Date:5/16/2013)... S.C. , May 16, 2013 ... in combination with a custom thin film transistor ... highest forensic quality roll image in the smallest ... today. Sherlock, an Appendix F Mobile ID FAP ... a 95% reduction in size and weight when ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3Genetic risk for schizophrenia is connected to reduced IQ 2
... of 35 headwater basins in the United States and Canada ... rates was less than expected in many locations, suggesting that ... change. The study was just published in a special ... Long-Term Ecological Research (LTER) network of 26 sites around the ...
... Notre Dame,s Eck Institute for Global Health developed a ... drug resistance, an effort that will allow for real-time ... The new discovery is described in a paper appearing ... Science . The team of researchers includes Notre ...
... women will be diagnosed with breast cancer during her ... chance of successful treatment and long-term survival. However, early ... remains cumbersome, costly, and in many cases, cancer can ... based in the Dept. of Biomedical Engineering at McGill ...
Cached Biology News:Impact of warming climate doesn't always translate to streamflow 2Notre Dame researchers using novel method to combat malaria drug resistance 2Notre Dame researchers using novel method to combat malaria drug resistance 3Detecting breast cancer's fingerprint in a droplet of blood 2
... SilverQuest Silver Staining Kit is uniquely ... sensitivity with minimal protein modification for ... spectrometry problems associated with traditional silver ... kit because the reagents used do ...
...
... Insect Medium is formuatled for the ... Sf9 and Sf21 cells. Grace's Insect ... because it does not contain lactalbumin ... with transfection. Grace's Insect Medium, Supplemented ...
Schneider's Drosophila Medium is formulated for the expression of heterologous proteins in Drosophila S2 cells....
Biology Products: